Osinib
(Osimertinib INN) 80 mg Tablet is indicated for the treatment
of patients with metastatic epidermal growth factor receptor (EGFR) T790M
mutation-positive non-small cell lung cancer (NSCLC), as detected by an
FDA-approved test, whose disease has progressed on or after EGFR tyrosine
kinase inhibitor (TKI) therapy.
